B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$;

or a pharmaceutically acceptable salt thereof.

REMARKS

Claims 1-20 are pending. Claims 10-15 have been allowed, claims 1, 5-7 and 20 have been rejected, and claims 1-9 and 16-20 have been objected to. Claims 1-2 and 4-6 have been amended to place the claims in condition for allowance, or in better condition for appeal; entry of these amendments is respectfully requested. Reconsideration of the application in view of the amendments and remarks contained herein is respectfully requested.

The Examiner has repeated the requirement to elect a species and has stated that the claims will be "examined to the extent they read on R5 is L3 and M3 is (phenyl(CH2)nCOOH." Applicants assume that the Examiner means to refer to compounds in which R_5 is $-L_3-M_3$, and in which M_3 is phenyl$(CH_2)_n$COOH wherein the phenyl ring is optionally substituted with a reasonable group of substitutents. Applicants have amended claims 1-2 and 4-6 so that all the claims are limited in this respect. Applicants reserve the right to file divisional applications directed to the subject matter deleted from the claims by these amendments.

Claims 1, 5-7, and 20 have been rejected under 35 U.S.C. § 102(b) as being anticipated by Archer (3,189,617). The Examiner has indicated that when R_3 is OH and L^1 is a bond the claimed compound is the enol form of the ketone in reference example D2. Applicants traverse this rejection for the reasons set forth below.

In the claims as amended herein, R_3 cannot be OH, due to the proviso in the definition of M^1. Therefore, the claims do not cover the enol form of the ketone of Archer. The cited art does not teach or suggest the claimed compounds. For these reasons, Applicants respectfully request withdrawal of this rejection.

Claims 1-9 and 16-20 are objected to as being directed to "a misjoinder of inventions as recited above." Applicants traverse this objection. The claims are limited in scope in

accordance with the restriction required by the Examiner, as discussed above. Therefore, there is no basis for the present objection and Applicants respectfully request the withdrawal thereof.

Applicants respectfully request the allowance of all of claims 1-20, and prompt advancement of the case to issue. No fee is believed to be due herewith, but should a fee be due it should be charged to Deposit Acct. No. 01-1425.



Joseph M. Mazzarese

Reg. No. **32,803**

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940-0874
Tel. No. (973) 683-**2150**

Version With Markings To Show Changes Made

1 (Twice Amended). A compound of the formulae:



wherein:

R_1 and $R_{1'}$ are independently selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, $-S-C_1-C_{10}$ alkyl, C_1-C_{10} alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

or a moiety of the formulae:



R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-C(O)CH_3$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

R_7 is selected from $-(CH_2)_n-COOH$, $-(CH_2)_n-N-(C_1-C_6$ alkyl$)_2$, $-(CH_2)_n-NH-(C_1-C_6$ alkyl), $-CF_3$, C_1-C_6 alkyl, C_3-C_5 cycloalkyl, C_1-C_6 alkoxy, $-NH-(C_1-C_6$ alkyl), $-N-(C_1-C_6$ alkyl$)_2$,

pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$phenyl, phenyl,-O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl, -$(CH_2)_n$-phenyl-O-phenyl, -$(CH_2)_n$-phenyl-CH_2-phenyl, -$(CH_2)_n$-O-phenyl-CH_2-phenyl, -$(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$,the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -NH_2, -NO_2, -CF_3,CO_2H, or -OH;

R_2 is selected from H, halogen, -CF_3, -OH, -C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CHO, -CN, -NO_2, -NH_2, -NH-C_1-C_6 alkyl, -N(C_1-C_6 alkyl)$_2$, -N-SO_2-C_1-C_6 alkyl, or -SO_2-C_1-C_6 alkyl;

R_3 is selected from H, -CF_3, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, -C_1-C_6 alkyl, -C_3-C_{10} cycloalkyl, -CHO, halogen, $(CH_2)_nC(O)NH_2$ or a moiety of the formula – L^1-M^1:

L^1 indicates a linking or bridging group of the formulae -$(CH_2)_n$-, -S-, -O-, -C(O)-, -$(CH_2)_n$-C(O)-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-, or -$(CH_2)_n$-S-$(CH_2)_n$-, C(O)C(O)X, -$(CH_2)_n$-N-$(CH_2)_n$-;

M^1 is selected from the group consisting of:

a) H, [the group of] C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl, [or] and benzyl, the cycloalkyl, phenyl [or] and benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -NO_2, -NH_2, -CN, [or] and -CF_3, with the proviso that M^1 cannot be H when L^1 is -O-; [or]

b) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -NO_2, -NH_2, -CN, or -CF_3; [or]

c) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CHO, -NO_2, -NH_2, -CN, -CF_3 or -OH; [or] and

d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH;

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(CH_2)_n$-C_3-C_6 cycloalkyl, $-(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, $-(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or the groups of:

a) $-(CH_2)_n$-phenyl-O-phenyl, $-(CH_2)_n$-phenyl-CH_2-phenyl, $-(CH_2)_n$-O-phenyl-CH_2-phenyl, $-(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$, or a moiety of the formulae:



wherein n is independently selected in each appearance as an integer from 0 to 3, Y is C_3-C_5 cycloalkyl, phenyl, benzyl, napthyl, pyridinyl, quinolyl, furyl, thienyl or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$ or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O; or

b) a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n$-S-A, or $-(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$; or

c) a moiety of the formulae:



,



,



,



,



, or



;

wherein Z is O or S and the phenyl and pyrimidinyl rings of each moiety are optionally and independently substituted by from 1 to 3 substituents selected from halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, $-NH_2$, or $-NO_2$; or

d) a moiety of the formula $-L^2-M^2$, wherein:

L^2 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, -S-, -O-,

$-SO_2-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, $-C(O)C(O)X$;
where X = O, N

M^2 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

i) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

ii) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH; or

iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH;

n is an integer from 0 to 3;

R_5 is [selected from -COOH, -C(O)-COOH, $-(CH_2)_n-C(O)-COOH$, $-(CH_2)_n-COOH$, $(CH_2)_n-CH=CH-COOH$, $-(CH_2)_n$-tetrazole, $-CH_2$-phenyl-C(O)-benzothiazole, or



,


,



,



;

or] a moiety selected from the formulae $-L^3-M^3$[;]

wherein L^3 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, -S-, -O-, $-SO_2-$, -C(O)-, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$,$-(CH_2)_n-S-(CH_2)_n-$, $-C(Z)-N(R_6)-$, $-C(Z)-N(R_6)-(CH_2)_n-$, $-C(O)-C(Z)-N(R_6)-$, $-C(O)-C(Z)-N(R_6)-(CH_2)_n-$, $-C(Z)-NH-SO_2-$, $-C(Z)-NH-SO_2-(CH_2)_n-$, $-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O-$;

M^3 is [selected from the group of -COOH, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole,



,


,



,


,


,


,


,

,

or

, or


where R_8, R_9 or R_{10} can be attached anywhere in the cyclic or bicyclic system,]



---

and n is an integer from 0 to 3;

[R_8, in each appearance, is independently selected from H, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,


, or

;

n is an integer from 0 to 3;]

R_9 is selected from H, halogen, -CF_3, -OH, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, -C_1-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), or -N(C_1-C_6 alkyl)$_2$;

n is an integer from 0 to 3;

[R_{10} is selected from the group of H, halogen, -CF_3, -OH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, -C_1-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$,


,

,

,



,



,

or



,

or



,



,



,



,





,



, or



;

R_{11} is selected from H, C_1-C_6 lower alkyl, C_1-C_6 cycloalkyl, -CF_3, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH,



,



;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, R_{10}, and/or R_{11} shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,



n is an integer from 0 to 3;]
or a pharmaceutically acceptable salt thereof.

2 (Twice Amended). A compound of Claim 1 wherein:

R_1 and $R_{1'}$ are independently selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, $-S-C_1-C_{10}$ alkyl, C_1-C_{10} alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, or -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

M^1 is selected from: H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl [or] and benzyl, the cycloalkyl, phenyl [or] and benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $-NO_2$, $-NH_2$, -CN, [or] and $-CF_3$, with the proviso that M^1 cannot be H when L^1 is -O-;

R_4 is a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3 substituents selected from H, halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$;
or a pharmaceutically acceptable salt thereof.

4 (Twice Amended). A compound of Claim 1 wherein:

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, -$(CH_2)_n$-C_3-C_6 cycloalkyl, -$(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, -$(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or the groups of:

a) a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or -CF_3;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or -NO_2; or

b) a moiety of the formula -L^2-M^2, wherein L^2 and M^2 are as defined in claim 1;

[R_5 is selected from -COOH, -C(O)-COOH, -$(CH_2)_n$-C(O)-COOH, -$(CH_2)_n$-COOH, $(CH_2)_n$-CH=CH-COOH, -$(CH_2)_n$-tetrazole, -CH_2-phenyl-C(O)-benzothiazole, or



;

or a moiety selected from the formulae –L^3-M^3 wherein L^3 and M^3 are as defined in claim 1;] or a pharmaceutically acceptable salt thereof.

5 (Twice Amended). A compound of Claim 1 wherein:

R_1, is H;

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, -$(CH_2)_n$-C_3-C_6 cycloalkyl, -$(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, -$(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or -CF_3;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or -NO_2;

[R_5 is selected from -COOH, -C(O)-COOH, -$(CH_2)_n$-C(O)-COOH, -$(CH_2)_n$-COOH, $(CH_2)_n$-CH=CH-COOH, -$(CH_2)_n$-tetrazole, or



;

or a moiety selected from the formulae –L^3-M^3;

wherein L^3 is a bridging or linking moiety selected from a chemical bond, -$(CH_2)_n$-, -SO_2-, -C(O)-, -$(CH_2)_n$-C(O)-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-,-$(CH_2)_n$-S-$(CH_2)_n$-, -$(CH_2)_n$-SO-$(CH_2)_n$-, -$(CH_2)_n$-SO_2-$(CH_2)_n$-, or –$(CH_2)_n$-CH=CH-$(CH_2)_n$-O-;

M^3 is selected from the group of -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole,





,



,



where R_8, R_9 can be attached anywhere in the cyclic or bicyclic system,
n is an integer from 0 to 3;

R_8, in each appearance, is independently selected from H, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,



n is an integer from 0 to 3;

R_9 is selected from H, halogen, -CF_3, -OH, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, -C_1-C_6 alkyl, -O-C_1-C_6 alkyl, -NH(C_1-C_6 alkyl), or -N(C_1-C_6 alkyl)$_2$;
n is an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,



n is an integer from 0 to 3;]
or a pharmaceutically acceptable salt thereof.

6 (Twice Amended). A compound of Claim 1 wherein:

R_1 is selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, $-S-C_1-C_{10}$ alkyl, C_1-C_{10} alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

or R_1 and $R_{1'}$ are independently a moiety of the formulae:

or a moiety of the formulae:



R_6 and R_7 are as defined in claim 1;

R_3 is selected from H, $-CF_3$, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, $-C_1-C_6$ alkyl, $-C_3-C_{10}$ cycloalkyl, -CHO, halogen, $(CH_2)_nC(O)NH_2$ or a moiety of the formula $-L^1-M^1$:

L^1 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, $C(O)C(O)X$, $-(CH_2)_n-N-(CH_2)_n$;

M^1 is selected from H, the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$;

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(CH_2)_n-C_3-C_6$ cycloalkyl, $-(CH_2)_n-S-(CH_2)_n-C_3-C_5$ cycloalkyl, $-(CH_2)_n-O-(CH_2)_n-C_3-C_5$ cycloalkyl, or a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or -CF_3;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or -NO_2;

[R_5 is selected from -COOH, -C(O)-COOH, -$(CH_2)_n$-C(O)-COOH, -$(CH_2)_n$-COOH, $(CH_2)_n$-CH=CH-COOH, -$(CH_2)_n$-tetrazole, or a moiety selected from the formulae –L^3-M^3; wherein L^3 is a bridging or linking moiety selected from a chemical bond, -$(CH_2)_n$-, -$(CH_2)_n$-C(O)-$(CH_2)_n$-, -$(CH_2)_n$-O-$(CH_2)_n$-,-$(CH_2)_n$-S-$(CH_2)_n$-, -$(CH_2)_n$-SO-$(CH_2)_n$-, -$(CH_2)_n$-SO_2-$(CH_2)_n$-, or –$(CH_2)_n$-CH=CH-$(CH_2)_n$-O-;

M^3 is selected from the group of -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole,



where R_8, R_9 can be attached anywhere in the cyclic or bicyclic system,
n is an integer from 0 to 3;

R_8, in each appearance, is independently selected from H, -COOH, -$(CH_2)_n$-COOH, -$(CH_2)_n$-C(O)-COOH, tetrazole, -C(O)-NH_2, -$(CH_2)_n$-C(O)-NH_2,



n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-CF_3$, -OH, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-C_6 alkyl, $-O-C_1$-C_6 alkyl, $-NH(C_1$-C_6 alkyl), or $-N(C_1$-C_6 alkyl$)_2$;

n an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5, R_8, R_9, shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)-NH_2$, $-(CH_2)_n$-$C(O)-NH_2$,



,


,


or


;

n is an integer from 0 to 3;]

or a pharmaceutically acceptable salt thereof.